---
title: "China approves J&J's oral psoriasis pill, says drugmaker"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297158718.md"
datetime: "2026-08-27T09:38:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297158718.md)
  - [en](https://longbridge.com/en/news/297158718.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297158718.md)
generator: "portal-rs"
---

# China approves J&J's oral psoriasis pill, says drugmaker

(adding context on psoriasis, psoriasis drugs, and the market in paragraphs 1-5)

SHANGHAI, Aug 27 (Reuters) - China’s drug regulator has approved Johnson & Johnson’s (JNJ.N) oral pill for psoriasis, ​the company said on Thursday, intensifying competition in the world’s second-largest pharmaceutical market with rivals including Bristol Myers Squibb (BMY.N) and AbbVie (ABBV.N) . Psoriasis, a chronic autoimmune condition that causes itchy, scaly, and inflamed patches of skin, affects more than 8.4 million patients in China, according to J&J. Other treatments include its own Tremfya, Bristol Myers’ Sotyktu and AbbVie’s Skyrizi. Wall ​Street analysts have said J&J’s drug, Icotrokinra, has “blockbuster potential” as a safe and effective oral medication and that the once-daily medication could capture significant market share from injectables, such as Skyrizi and ​Tremfya. It was approved in China for moderate-to-severe plaque psoriasis, J&J said in a statement. A spokesperson for J&J did not immediately respond to a request for comment outside business hours on availability, pricing or sales expectations for the local market. Other drugmakers including China’s Innocare Pharma (688428.SS) and Japan’s Takeda Pharmaceutical (4502.T) are also developing experimental oral treatments in a global market largely dominated by injectables.

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)
- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)
- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Focus Partners Advisor Solutions LLC Boosts Position in AbbVie Inc. $ABBV](https://longbridge.com/en/news/297140864.md)
- [First National Bank of Omaha Purchases 8,167 Shares of AbbVie Inc. $ABBV](https://longbridge.com/en/news/297396117.md)
- [Meeder Asset Management Inc. Boosts Stake in AbbVie Inc. $ABBV](https://longbridge.com/en/news/297398087.md)
- [SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings | ABBV Stock News](https://longbridge.com/en/news/297650111.md)
- [Trivium Point Advisory LLC Increases Stock Holdings in AbbVie Inc. $ABBV](https://longbridge.com/en/news/297292955.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**